Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
September 21, 2021 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare...
Kiniksa Announces Launch of ARCALYST Named Patient Program
August 16, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Named Patient Program supports patient access to ARCALYST® (rilonacept) in countries where ARCALYST is not currently commercially available - HAMILTON, Bermuda, Aug. 16, 2021 (GLOBE NEWSWIRE)...
Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
August 03, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Q2 2021 ARCALYST® (rilonacept) net revenue of $7.7 million with greater than 100 prescribing physicians - - Phase 3 data from mavrilimumab clinical trial in COVID-19-related ARDS on-track for Q1...
Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
August 02, 2021 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday,...
Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021
July 20, 2021 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, July 20, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, August 3, 2021 at...
Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis
June 08, 2021 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 08, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate...
Kiniksa Outlines Next Steps for the Development of Mavrilimumab
June 08, 2021 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Defined regulatory pathway for Phase 3 clinical development of mavrilimumab in multiple indications - - Continued development in COVID-19-related ARDS represents fastest path to potential...
Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference
June 01, 2021 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 01, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Goldman Sachs 42nd Annual Global Healthcare...
Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
May 04, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- ARCALYST® (rilonacept) launched as the first and only FDA-approved therapy for recurrent pericarditis -- Mavrilimumab Phase 2 severe COVID-19 data demonstrated a reduction in mechanical ventilation...
Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404
May 04, 2021 07:59 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Highest dose cohorts confirm and extend previously-reported 3 mg/kg IV cohort data -- 10 mg/kg IV dose provides full receptor occupancy through Day 71 and complete suppression of TDAR after KLH...